For research and educational purposes only. Not medical advice.
Tamoxifen citrate Reference
Educational, not medical advice reference for Tamoxifen citrate: Hormonal; regulatory status, evidence posture, source review, and schedule notes. Also known…
Reference summary
On-label breast-cancer evidence is mature. The off-label male use cases (gynecomastia treatment, HPTA-recovery contexts) have small randomized and case-series data; Wibowo 2016 Andrology reviewed adverse events in men. Tamoxifen has documented thromboembolic risk in women and the same class concern applies to off-label male use.
Regulatory and posture
- Categories
- Hormonal
- Aliases
- Nolvadex, Soltamox, Selective estrogen receptor modulator (small molecule, not a peptide)
- Evidence posture
- human - Off-label male gynecomastia and HPTA-recovery use is investigational. Thromboembolic risk is real even in men. Hepatotoxicity at high doses.
- Regulatory status
- FDA-approved for the treatment of metastatic breast cancer, adjuvant treatment of breast cancer, and reduction in breast-cancer incidence in high-risk women. Off-label use in men for treatment of gynecomastia and HPTA-recovery contexts after anabolic-androgenic-steroid exposure exists in clinical practice but is not an FDA-approved indication. WADA-prohibited at all times under S4.
- Content review status
- label verified